✦ LIBER ✦

Magnetic Resonance Spectroscopy of cancer—practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma

✍ Scribed by J.R. Griffiths; A.R. Tate; F.A. Howe; M. Stubbs

Book ID: 117659110
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 278 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)00389-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Human interferon alpha in malignant lymp

Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial

✍ Sandra J. Horning; Thomas C. Merigan; Susan E. Krown; Jordan U. Gutterman; Arthu 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 604 KB

Late Non-Neoplastic Events in Patients w

Late Non-Neoplastic Events in Patients with Aggressive Non-Hodgkin's Lymphoma in Four Randomized European Organisation for Research and Treatment of Cancer Trials

✍ Moser, Elizabeth C.; Noordijk, Evert M.; Carde, Patrice; Tirelli, Umberto; Baars 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 907 KB

Histology and stage stratified therapy o

Histology and stage stratified therapy offers promising results in primary gastric non-Hodgkin's lymphoma: Experiences of the German-Austrian prospective multicenter trial

✍ Fischbach, W; Kolve, M.-E.; Dragosics, B.; Greiner, A.; Müller-Hermelink, H.K.; 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Phase II trial of ifosfamide and mesna i

Phase II trial of ifosfamide and mesna in previously treated patients with non-hodgkin's lymphoma: Cancer and leukemia group b study 8552

✍ Delvyn C. Case JR; James Anderson; Thomas J. Ervin; Arlan Gottlieb 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 522 KB

## Abstract Ifosfamide (1·25 g/m^2^ intravenously/day × 5) with mesna (20 per cent of the ifosfamide dose × six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non‐Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29 per cent response rat

Phase II trial of ifosfamide and mesna i

Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552

✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351

✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated